The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

6-month update on the phase III VIALE-C trial

Jul 16, 2020

During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Andrew Wei, The Alfred, Melbourne, AU, who provided information on the 6-month update of the phase III VIALE-C trial.

6-month update on the phase III VIALE-C trial

The current standard of care for elderly patients with AML is cytarabine (Ara-C), however, response rates are modest, and alternative therapeutic strategies are required. The VIALE-C study is evaluating venetoclax in combination with low-dose Ara-C for the treatment of elderly patients with AML. Here, Andrew Wei outlines the study design and patient responses to Ara-C + venetoclax vs Ara-C + placebo.